This trial will test a new drug, ALXN1720, for the treatment of generalized myasthenia gravis (gMG) in adults. gMG is a disease where the body's immune system attacks healthy cells, causing muscle weakness. The new drug is designed to stop the immune system from attacking healthy cells.
1 Primary · 4 Secondary · Reporting Duration: Baseline, Week 26
254 Total Participants · 2 Treatment Groups
Primary Treatment: ALXN1720 · Has Placebo Group · Phase 3
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: